Reuters logo
BRIEF-Adello Biologics says FDA accepts for review co's Biologics License Application for proposed filgrastim biosimilar
September 11, 2017 / 5:17 PM / 2 months ago

BRIEF-Adello Biologics says FDA accepts for review co's Biologics License Application for proposed filgrastim biosimilar

Sept 11 (Reuters) - Adello Biologics:

* FDA accepts Adello Biologic’s biosimilar biologics license application for a proposed filgrastim biosimilar

* U.S. FDA has accepted for review co’s Biologics License Application (BLA) for a biosimilar candidate referencing neupogen (filgrastim)​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below